These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 36688961)
21. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells. Yeh CH; Peng HC; Yang RS; Huang TF Mol Pharmacol; 2001 May; 59(5):1333-42. PubMed ID: 11306719 [TBL] [Abstract][Full Text] [Related]
22. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab. Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003 [TBL] [Abstract][Full Text] [Related]
23. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Gautam A; Densmore CL; Melton S; Golunski E; Waldrep JC Cancer Gene Ther; 2002 Jan; 9(1):28-36. PubMed ID: 11916242 [TBL] [Abstract][Full Text] [Related]
24. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related]
25. Recombinant snake venom cystatin inhibits tumor angiogenesis in vitro and in vivo associated with downregulation of VEGF-A165, Flt-1 and bFGF. Xie Q; Tang N; Wan R; Qi Y; Lin X; Lin J Anticancer Agents Med Chem; 2013 May; 13(4):663-71. PubMed ID: 23094915 [TBL] [Abstract][Full Text] [Related]
26. Beta-carotene inhibits tumor-specific angiogenesis by altering the cytokine profile and inhibits the nuclear translocation of transcription factors in B16F-10 melanoma cells. Guruvayoorappan C; Kuttan G Integr Cancer Ther; 2007 Sep; 6(3):258-70. PubMed ID: 17761639 [TBL] [Abstract][Full Text] [Related]
27. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas. Seguin F; Carvalho MA; Bastos DC; Agostini M; Zecchin KG; Alvarez-Flores MP; Chudzinski-Tavassi AM; Coletta RD; Graner E Br J Cancer; 2012 Sep; 107(6):977-87. PubMed ID: 22892389 [TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding. Graziani G; Ruffini F; Tentori L; Scimeca M; Dorio AS; Atzori MG; Failla CM; Morea V; Bonanno E; D'Atri S; Lacal PM Oncotarget; 2016 Nov; 7(45):72868-72885. PubMed ID: 27655684 [TBL] [Abstract][Full Text] [Related]
29. Grateloupia longifolia polysaccharide inhibits angiogenesis by downregulating tissue factor expression in HMEC-1 endothelial cells. Zhang C; Yang F; Zhang XW; Wang SC; Li MH; Lin LP; Ding J Br J Pharmacol; 2006 Jul; 148(6):741-51. PubMed ID: 16715123 [TBL] [Abstract][Full Text] [Related]
30. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma. Shiose S; Sakamoto T; Yoshikawa H; Hata Y; Kawano Y; Ishibashi T; Inomata H; Takayama K; Ueno H Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2395-403. PubMed ID: 10937546 [TBL] [Abstract][Full Text] [Related]
31. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma. Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924 [TBL] [Abstract][Full Text] [Related]
32. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo. Rastelli L; Valentino ML; Minderman MC; Landin J; Malyankar UM; Lescoe MK; Kitson R; Brunson K; Souan L; Forenza S; Goldfarb RH; Rabbani SA Int J Oncol; 2011 Aug; 39(2):401-8. PubMed ID: 21567086 [TBL] [Abstract][Full Text] [Related]
33. A fusion protein with the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2. Tseng FJ; Chen YC; Lin YL; Tsai NM; Lee RP; Chung YS; Chen CH; Liu YK; Huang YS; Hwang CH; Lai YK; Liao KW Cancer Biol Ther; 2010 Nov; 10(9):865-73. PubMed ID: 20818186 [TBL] [Abstract][Full Text] [Related]
34. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
35. Delphinidin Inhibits Tumor Growth by Acting on VEGF Signalling in Endothelial Cells. Keravis T; Favot L; Abusnina AA; Anton A; Justiniano H; Soleti R; Alabed Alibrahim E; Simard G; Andriantsitohaina R; Lugnier C PLoS One; 2015; 10(12):e0145291. PubMed ID: 26694325 [TBL] [Abstract][Full Text] [Related]
36. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Yang H; Jager MJ; Grossniklaus HE Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):2835-42. PubMed ID: 20089875 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of tumor specific angiogenesis by amentoflavone. Guruvayoorappan C; Kuttan G Biochemistry (Mosc); 2008 Feb; 73(2):209-18. PubMed ID: 18298378 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of Antiangiogenic Efficacy of Emilia sonchifolia (L.) DC on Tumor-Specific Neovessel Formation by Regulating MMPs, VEGF, and Proinflammatory Cytokines. Gilcy GK; Kuttan G Integr Cancer Ther; 2016 Dec; 15(4):NP1-NP12. PubMed ID: 27146127 [TBL] [Abstract][Full Text] [Related]
39. Antiangiogenic and antitumoral effects mediated by a vascular endothelial growth factor receptor 1 (VEGFR-1)-targeted DNAzyme. Shen L; Zhou Q; Wang Y; Liao W; Chen Y; Xu Z; Yang L; Sun LQ Mol Med; 2013 Nov; 19(1):377-86. PubMed ID: 24306423 [TBL] [Abstract][Full Text] [Related]
40. "Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Rybak SM; Sanovich E; Hollingshead MG; Borgel SD; Newton DL; Melillo G; Kong D; Kaur G; Sausville EA Cancer Res; 2003 Jun; 63(11):2812-9. PubMed ID: 12782586 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]